About this trial
Endoscopic submucosal dissection (ESD) is commonly performed for (pre)cancerous lesions in the esophagus. Following ESD, post-procedural chest pain is seen in many patients. Studies have shown that local bupivacaine (BP) into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively. Levobupivacaine (LB) is equipotent to BP regarding analgesic effects, but has a better safety profile. No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain. Therefore, we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD.
Eligibility criteria
Qualifiers
Patients age ≥18 years at time of consent
Visible lesion in the esophagus, minimum diameter of the lesion ≥20 mm
Scheduled for esophageal ESD
Informed consent
Disqualifiers
Presence of multiple lesions requiring two or more separate endoscopic resections
History of esophageal surgery other than fundoplications
History of esophageal ablation therapy
History of radiotherapy of the esophagus
Trial design
Treatments tested in this trial
- Local levobupivacaine
Treatment groups
Sponsors and collaborators
Laura Boer
Lead sponsor
St. Antonius Hospital
Sponsor institution